LRRK2 and Parkinson disease: The expression of some of these genes was partially recovered after the treatment of the mutant LRRK2-G2019S hMOs with a LRRK2 kinase inhibitor, suggesting that these 3D cellular model can be also used for drug screening and for the investigation of PD therapeutic options [52].